Holen Sie sich die Stockscreener-App
3.54
3.54%
-0.13
Schlusskurs vom Vortag:
$3.67
Offen:
$3.67
24-Stunden-Volumen:
687.08K
Relative Volume:
5.21
Marktkapitalisierung:
$250.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-2.97M
KGV:
-3.583
EPS:
-0.988
Netto-Cashflow:
$-1.18M
1W Leistung:
-26.25%
1M Leistung:
+52.59%
6M Leistung:
-58.11%
1J Leistung:
-75.97%
1-Tages-Spanne:
$3.29
$3.88
1-Wochen-Bereich:
$3.10
$4.87
52-Wochen-Spanne:
$1.70
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
3.54 | 338.98M | 0 | -2.97M | -1.18M | -0.988 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Yd Bio Ltd Aktie (YDES) Neueste Nachrichten
ETFs Investing in YD Bio Limited Stocks - TradingView
Top movers in Tuesday's pre-market session - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day - RTTNews
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
YD Bio Ord Shs (YDES) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem - TipRanks
YD Bio launches nutrition products via physician partnership model By Investing.com - Investing.com Australia
YD Bio launches nutrition products via physician partnership model - Investing.com
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute - Yahoo Finance
Two New Nutrition Formulas Bring YD Bio Into Taiwan Physician Network - Stock Titan
Top YD Bio (YDES) Competitors 2026 - MarketBeat
YD Bio Ord Shs (YDES) Stock News Today - TradingKey
Lantheus Holdings (LNTH) Holds Near $101 as Buyers Defend Key SupportForce Index - vinanet.vn
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research - Yahoo Finance
Keratoconus Study Ranks Molecules for Future Corneal Therapy Research - Stock Titan
YD Bio Launches Cross-Border Cancer Testing Pilot in Canada - Clinical Lab Products
YD Bio Limited (YDES) Climbs 5.55% to $2.32 as Buyers Eye Key ResistanceMFI Oversold - dars.gov.et
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada - The Manila Times
YD Bio launches pilot for cancer testing in British Columbia By Investing.com - Investing.com Canada
Five Cancer Types Targeted in YD Bio's Cross-Border Pilot - Stock Titan
Y.D. More group (TATT) reports 5.42% beneficial stake in TAT Technologies - Stock Titan
YD Bio Ord Shs (YDES) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
YD Bio Ord Shs (YDES) Cash Flow - TradingKey
YDES|YD Bio Ord Shs|Price:2.350|Chg%:+0.110 - TradingKey
YD Bio Ord Shs (YDES) Balance Sheet - TradingKey
YDES|YD Bio Ord Shs|Price:2.300|Chg%:-0.020 - TradingKey
YD Bio Ord Shs (YDES) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
YD Bio Ord Shs (YDES) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
YD Bio Ord Shs (YDES) Institutional Confidence - TradingKey
YD Bio Ord Shs (YDES) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
YD Bio Ord Shs (YDES) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
YDES|YD Bio Ord Shs|Price:2.240|Chg%:+0.200 - TradingKey
YD Bio Ord Shs (YDES) Income Statement - TradingKey
YD Bio Limited (YDES) Surges 7.7% as Shares Test Key Resistance at $2.35Statistical Arbitrage - dars.gov.et
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services - The Manila Times
30 Prospective Partners Explore Cancer Tests and Eye Care at Taiwan Expo - Stock Titan
Diabetic Macular Edema Pipeline 2026: MOA, ROA, FDA-Approved - openPR.com
Gapping stocks in Wednesday's session - ChartMill
YDESW Warrants Surge 6.67%: Key Levels and Technical Outlook for YD Bio Limited WarrantsCollar Trade - dars.gov.et
Enterprise value to revenue forward of YD Bio Limited – NASDAQ:YDES - TradingView
Enterprise value to EBIT forward of YD Bio Limited – NASDAQ:YDES - TradingView
PLPC Q1 2026 Earnings: EPS Surprises to the Upside, but Stock DeclinesAnnual Report - dars.gov.et
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Which stocks have an unusual volume on Tuesday? - ChartMill
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
YD Bio (YDESW) Stock Analysis Report | Financials & Insights - Benzinga España
YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania - Investing.com
YD Bio affiliate obtains lab licenses in Rhode Island, Pennsylvania By Investing.com - Investing.com Canada
YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection Operations - Yahoo Finance
YD Bio expands cancer-testing lab access to 46 states - Stock Titan
Finanzdaten der Yd Bio Ltd-Aktie (YDES)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):